EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nextage Therapeutics's enterprise value is ₪27.73 Mil.
Nextage Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-3.75 Mil. Therefore, Nextage Therapeutics's EV-to-EBITDA for today is -7.39.
The historical rank and industry rank for Nextage Therapeutics's EV-to-EBITDA or its related term are showing as below:
XTAE:NXTG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.01 Med: -2.2 Max: -0.74
Current: -7.39
During the past 8 years, the highest EV-to-EBITDA of Nextage Therapeutics was -0.74. The lowest was -9.01. And the median was -2.20.
XTAE:NXTG's EV-to-EBITDA is ranked worse than 100% of 704
companies
in the Drug Manufacturers industry
Industry Median: 14.56
vs XTAE:NXTG: -7.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Nextage Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Nextage Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nextage Therapeutics's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nextage Therapeutics's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nextage Therapeutics's EV-to-EBITDA falls into.
Nextage Therapeutics's current Enterprise Value is ₪27.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nextage Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-3.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nextage Therapeutics's PE Ratio for today is calculated as:
Nextage Therapeutics's share price for today is ₪0.869.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nextage Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Nextage Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Nextage Therapeutics (XTAE:NXTG) Business Description
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTAE:NXTG has been successfully added to your 